Technical Analysis for VRPX - Virpax Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 10.44% | |
| 50 DMA Resistance | Bearish | 10.44% | |
| MACD Bearish Centerline Cross | Bearish | 10.44% | |
| 180 Bearish Setup | Bearish Swing Setup | 10.44% | |
| BB Squeeze Ended | Range Expansion | 10.44% | |
| Bollinger Band Squeeze | Range Contraction | 5.23% | |
| Gapped Up | Strength | 5.23% | |
| MACD Bearish Signal Line Cross | Bearish | 9.39% | |
| Bollinger Band Squeeze | Range Contraction | 9.39% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 9.39% |
| Alert | Time |
|---|---|
| 10 DMA Support | 3 minutes ago |
| 50 DMA Support | 3 minutes ago |
| Rose Above 50 DMA | 3 minutes ago |
| Rose Above 10 DMA | 3 minutes ago |
| Possible Inside Day | 3 minutes ago |
Get a Trading Assistant
- Earnings date: 05/14/2024
Virpax Pharmaceuticals, Inc. Description
Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Health Sciences Drugs Euphoriants Opioids Influenza Pain Management Drug Delivery Analgesics Morphinans Post Traumatic Stress Disorder Heroin Drug Delivery Systems Morphine Bupivacaine Nasal Administration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.199 |
| 52 Week Low | 0.3625 |
| Average Volume | 198,788 |
| 200-Day Moving Average | 1.77 |
| 50-Day Moving Average | 0.67 |
| 20-Day Moving Average | 0.68 |
| 10-Day Moving Average | 0.68 |
| Average True Range | 0.08 |
| RSI (14) | 43.50 |
| ADX | 18.91 |
| +DI | 22.75 |
| -DI | 20.09 |
| Chandelier Exit (Long, 3 ATRs) | 0.55 |
| Chandelier Exit (Short, 3 ATRs) | 0.74 |
| Upper Bollinger Bands | 0.78 |
| Lower Bollinger Band | 0.58 |
| Percent B (%b) | 0.17 |
| BandWidth | 29.26 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0084 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.74 | ||||
| Resistance 3 (R3) | 0.75 | 0.72 | 0.72 | ||
| Resistance 2 (R2) | 0.72 | 0.69 | 0.72 | 0.71 | |
| Resistance 1 (R1) | 0.67 | 0.67 | 0.65 | 0.66 | 0.70 |
| Pivot Point | 0.64 | 0.64 | 0.63 | 0.63 | 0.64 |
| Support 1 (S1) | 0.59 | 0.61 | 0.57 | 0.57 | 0.53 |
| Support 2 (S2) | 0.56 | 0.59 | 0.55 | 0.52 | |
| Support 3 (S3) | 0.50 | 0.56 | 0.51 | ||
| Support 4 (S4) | 0.49 |
